{"id":"W1851453522","doi":"10.1111/apt.13402","title":"Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases","year":2015,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials","funders":"UCB Pharma; Genentech; Vlaamse regering; Hellenic Society of Gastroenterology; Norgine; Agentschap voor Innovatie door Wetenschap en Technologie; Fonds Wetenschappelijk Onderzoek; Celltrion; European Crohn's and Colitis Organisation; National Institute for Health and Care Research; Janssen Biotech; Teva Pharmaceutical Industries; Celgene; Pfizer; Biogen; Ablynx; Gilead Sciences; Amgen; ActoGeniX; Sanofi; Tillotts Pharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Biosimilar; Medicine; Infliximab; Adalimumab; Inflammatory bowel disease; Ulcerative colitis; Bioequivalence; Rheumatoid arthritis; Pharmacokinetics; Drug; Pharmacology; Crohn's disease; Pharmacodynamics; Ankylosing spondylitis; Internal medicine; Immunology; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001124364,0.0008751964,0.003196184,0.0003316675,0.00008930987,0.00001117199,0.0009467888,0.0009838981,0.003103543],"category_scores_gemma":[0.000003511319,0.000661906,0.0007554326,0.0006331071,0.001058064,0.0001034691,0.0004042133,0.001395939,0.0001837836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002575648,"about_ca_system_score_gemma":0.0005639981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006261509,"about_ca_topic_score_gemma":0.00000204639,"domain_scores_codex":[0.9934002,0.002963972,0.001766087,0.0008323728,0.0001314062,0.0009059181],"domain_scores_gemma":[0.9977746,0.0007032743,0.0007912051,0.0004478837,0.0001342393,0.0001488238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005128403,0.006029531,0.0009130871,0.04323849,0.0681273,0.0006048735,0.0001043559,0.000002955688,0.01794785,0.0001992204,0.09691641,0.7654031],"study_design_scores_gemma":[0.001607567,0.0003207263,0.00004823797,0.005144499,0.06251662,0.0001017495,0.00001490163,0.000003090104,0.003074684,0.000103598,0.9264272,0.0006371501],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002220922,0.993986,0.000001560567,0.001098417,0.001988083,0.00193225,0.0004518178,0.00007989355,0.0002398667],"genre_scores_gemma":[0.0001512967,0.9760308,0.00007532741,0.02305002,0.0001264817,0.0001736189,0.0002445239,0.00007003,0.00007785216],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8295107,"threshold_uncertainty_score":0.9995832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08557301642064606,"score_gpt":0.4069166715807467,"score_spread":0.3213436551601006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}